1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Published
The company has great potential if and when it enters the commercial stage.
Full ArticlePublished
The company has great potential if and when it enters the commercial stage.
Full ArticleRevenue growth during what should be a disastrous patent cliff is encouraging.
One Wall Street analyst thinks this phase of incredible growth for Nvidia is here to stay.